Home » 1: Pembrolizumab plus lenvatinib for previously untreated advanced non–clear cell renal cell carcinoma: 3-year follow-up of the phase 2 KEYNOTE-B61 study – PMC
1: Pembrolizumab plus lenvatinib for previously untreated advanced non–clear cell renal cell carcinoma: 3-year follow-up of the phase 2 KEYNOTE-B61 study – PMC
by Laurence Albiges, Howard Gurney, Jae Lyun Lee, Vagif Atduev, Cristina Suarez, Miguel A Climent, David Pook, Piotr Tomczak, Philippe Barthelemy, Craig Gedye, Louis Lacombe, Thomas Ferguson, Viktor Stus, Pawel Wiechno, Mustafa Erman, Yuksel Urun, Jerry Cornell, Joe Burgents, Manish Sharma & Martin Voss | Oct 10, 2025 | Articles |
